After a year of financial struggles, consumer genomics company 23andMe raised just under $82.5 million in equity funding, according to SEC filings. Veteran health tech investors Sequoia Capital and NewView Capital participated in this latest round, according to the Wall Street Journal.
Historically, 23andMe has had a number of large investments, including a $300 million investment from pharma...
23andMe announced this morning that it has received a 510(k) clearance from the FDA that allows its direct-to-consumer personal pharmacogenetics report to guide use of two treatments without the need for confirmatory testing.
WHAT HAPPENED
This action updates a De Novo approval granted to the consumer genomics company in late 2018. That decision allowed 23andMe to market a test for one of 33...
23andMe has laid off 100 employees across its consumer business, the genomics company confirmed to MobiHealthNews.
This news come amidst disappointing sales numbers, according to CNBC, which first reported the story. In an interview with CNBC’s Chrissy Farr, 23andMe CEO Anne Wojcicki discussed potential factors contributing to what she sees as a market cooldown, top of the list being customers...
Not so fast? Google’s plans to purchase Fitbit will soon be under the US Department of Justice’s lens. According to a New York Post report, the merger raised antitrust flags at both the DOJ and the Federal Trade Commission, with the former federal agency ultimately winning out.
The Post’s sources said that both of these agencies are hesitant to allow Google an even greater view into individuals’...
Shoppers may come home with more than they bargained for when visiting Waitrose & Partners Canary Wharf, and John Lewis & Partners, White City. As well as bagging their usual products, customers now have the chance to get a personalised DNA report while browsing the London stores.
Two pop-ups from genetic testing pioneer DnaNudge aim to 'nudge' people into make healthier choices by...
23andMe, a frontrunner in the consumer genomics space, is turning its attention to clinical trial recruitment. The company has inked a deal with TrialSpark, a health tech platform that lets providers become clinical trial sites, connecting their customers to the latter’s trial network.
The new deal will use 23andMe’s crowdsourced research platform, which lets its customers opt into research and...
Telehealth and mail-order health and wellness consumer brands Hims & Hers have been joined by Dr. Pat Carroll. Formerly a chief medical officer at Walgreens and a 20,000-patient primary care group, Carroll take on a similar role for the growing startup.
“Our vision is an ecosystem where people have plenty of options to get the care that’s right for them. Depending on what they need, that...
MyHeritage, an Israeli company that has been doing ancestry-related genetic testing since 2016, has announced a new product that brings the company into the health-focused consumer DNA testing space alongside the likes of 23andMe.
MyHeritage DNA Health+Ancestry is a single test that includes a wide-range of genetic aptitudes for possible health conditions: specifically, the company will offer 11...
This morning 23andMe announced that it is teaming up with The Michael J. Fox Foundation for Parkinson’s Research on a new data and analytics platform dedicated to Parkinson’s research.
The new tool, dubbed Fox Insight Data Exploration Network (Fox DEN) is set to include patient surveys, de-identified genetic data and data exploration tools all aimed studying Parkinson’s.
Users who opt into the...
Direct-to-consumer gene tests like Ancestry.com and 23andMe are increasingly informing consumers about gene alterations that could signal health risks. But those tests look at only a few positions on particular genes, as opposed to medical sequencing that is much more thorough. And, according to a 2018 study by Ambry Genetics in Genetics in Medicine, these results can be wrong — the study showed...
.jpeg?itok=HF3iI7dj "Person answering their front door and getting a delivery from another person")
